Company news
Adial Pharmaceuticals, Inc news in 2021
Adial Pharmaceuticals, Inc's news releases, calls and decks from 2021, newest first.
Adial Pharmaceuticals Completes Private Placement of Common Stock at $4.00 Per Share
December 21, 2021
Adial Announces Cary J. Claiborne, a Renowned Pharmaceutical Executive and Current Board Member, has Joined the Company as Chief Operating Officer
December 7, 2021
Adial Pharmaceuticals Announces Positive Pre-Clinical Data for PNV2 as a Drug Candidate for Triple Negative Breast Cancer
November 28, 2021
Adial Pharmaceuticals Announces Private Placement of Common Stock at $4.00 Per Share and Cash Exercise of Stock Options
November 9, 2021
Adial Pharmaceuticals Schedules Conference Call to Provide Clinical Update and Discuss Latest Developments
November 8, 2021
Adial Appoints Renowned Pharmaceutical Executive Cary J. Claiborne to Board of Directors
November 2, 2021
Adial Announces Positive Pre-Clinical Data for Purnovate’s PNV-5030 as Drug Candidate for the Treatment of Pain
October 20, 2021
Adial Pharmaceuticals Announces Greater Than 50% of Patients Expected to Complete ONWARD™ Phase 3 Trial of AD04 for the Treatment of Alcohol Use Disorder Have Completed the Full 24-Week Treatment Period – Trial Completion Anticipated Q1 2022
September 29, 2021
Adial Pharmaceuticals Announces Research Collaboration Agreement with the University of Virginia to Advance Next Generation Adenosine Compounds for Wound Healing
September 27, 2021
Adial Pharmaceuticals Exceeds Enrollment Target in ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder
August 30, 2021
Adial Pharmaceuticals Reaches Full Enrollment Target for ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients With Alcohol Use Disorder
August 19, 2021
Adial Pharmaceuticals Schedules Conference Call to Provide Clinical Update and Discuss Positive Business Developments
August 11, 2021
Adial Pharmaceuticals Awarded U.S. and International Patents for the Treatment Of Alcohol and Opioid Use Disorders Using AD04
August 9, 2021
Adial Pharmaceuticals Announces Closing of $5 Million Private Placement Priced at a Premium to Market
August 4, 2021
Adial Announces Positive Pre-Clinical Data for its Adenosine Pain Platform
July 13, 2021
Adial Announces $5,000,000 Above Market Private Placement at $3.00 Per Share
July 6, 2021
Adial Joins Russell Microcap® Index
June 27, 2021
Adial Pharmaceuticals Provides Regulatory and Development Update
June 23, 2021
Adial Pharmaceuticals Plans to Enter Genetic Testing Market Following Allowance of U.S. Patent for Genetic Diagnostic Test
June 21, 2021
Adial Announces Funding of Management-Led $2,100,000 Above Market Private Placement at $3.00 Per Share
June 2, 2021
Adial Announces Management-Led $2,100,000 Above Market Private Placement at $3.00 Per Share
March 14, 2021
Adial Receives $1.425 Million in Net Proceeds from Exercise of Warrants
February 25, 2021
Adial Pharmaceuticals Achieves 50% Enrollment in ONWARD™ Phase 3 Trial
February 24, 2021
Adial to File Fast Track Application for AD04 with the FDA
February 22, 2021
Adial Pharmaceuticals Closes Acquisition of Purnovate
January 25, 2021
Adial Pharmaceuticals Receives Notice of Allowance for Third U.S. Patent Covering AD04 for the Treatment for Opioid Use Disorder
January 10, 2021